Autonomix Medical, Inc. filings document a development-stage medical device company focused on precision nerve-targeted technology and transvascular approaches to peripheral nerve sensing and treatment. Securities registration statements describe the company’s common stock, warrant instruments, offering mechanics, emerging growth company status, smaller reporting company status, financial statements, convertible note proceeds, and related-party transaction disclosures.
Autonomix’s 8-K filings cover material events including Regulation FD clinical-data disclosures, private placement financing agreements involving pre-funded warrants and Series C warrants, annual meeting voting results, board and auditor matters, reverse stock split authority, and Nasdaq continued-listing compliance notices. These records also reflect capital-structure changes and governance actions tied to the company’s public-company status.
Autonomix Medical, Inc. (AMIX) is calling an annual stockholder meeting for October 29, 2026 to elect five directors, ratify Forvis Mazars, LLP as auditor, and vote on two key capital-structure items. Stockholders are asked to authorize the Board to implement a reverse stock split of outstanding common shares at a ratio between 1-for-2 and 1-for-25, at any time up to one year after the meeting, and to approve an amended and restated 2023 Equity Incentive Plan that would increase shares available for equity compensation. Stockholders of record on September 8, 2026, when 1,828,505 shares of common stock were outstanding, are entitled to one vote per share.
Autonomix Medical, Inc. (AMIX) is registering up to 1,071,826 shares of common stock for resale by a single selling stockholder, issuable upon exercise of Series E common stock purchase warrants at an exercise price of $6.25 per share.
Autonomix will not sell any shares in this offering and will receive cash only if the warrants are exercised, which, if fully exercised for cash, would generate up to about $6.7 million in gross proceeds, planned for working capital. As of August 31, 2026, 1,828,505 shares of common stock were outstanding. The company highlights that issuance of the warrant shares could materially dilute existing stockholders and that the volume of registered resale shares could pressure the trading price.
Autonomix recently effected a 1-for-21 reverse stock split, reducing outstanding common shares from 11,409,344 to 542,312 while keeping 500 million authorized shares unchanged. The independent auditor’s report on the March 31, 2026 financial statements includes an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern.
Autonomix Medical, Inc. (AMIX) entered into a warrant inducement transaction with an investor holding previously issued Series D-1 and D-2 warrants. The investor agreed to immediately exercise warrants to purchase 857,462 shares of common stock at an exercise price of $5.75 per share, generating expected gross proceeds of about $4.9 million before fees and expenses.
In consideration for this cash exercise, Autonomix will issue unregistered Series E-1 and Series E-2 warrants, each to purchase up to 535,913 shares of common stock, with a $6.25 exercise price and a 5-year term. The new warrants include a 4.99% or 9.99% Beneficial Ownership Limitation, are exercisable immediately, and may be exercised on a cashless basis under specified registration shortfalls. In a fundamental transaction, holders receive alternate consideration, and the Series E-2 warrants include a Black Scholes-based redemption right.
The new warrants are being issued in a private placement under Section 4(a)(2) of the Securities Act, and Autonomix agreed to file a resale registration statement for the underlying shares within set timeframes. Maxim Group LLC acted as financial advisor and warrant inducement agent, to receive a 7.0% cash fee on proceeds plus up to $15,000 in expense reimbursement.
Autonomix Medical, Inc. is a development-stage medical device company with no revenues, focused on catheter-based neural sensing and RF ablation for pain associated with pancreatic cancer and other nerve-related disorders. For the three months ended June 30, 2026, it reported a net loss of $2.7 million, compared with $3.3 million a year earlier, as operating expenses declined 19% to $2.8 million driven mainly by lower stock-based compensation and general and administrative costs.
As of June 30, 2026, Autonomix had cash of $3.5 million, total assets of $7.6 million, working capital of $3.1 million and an accumulated deficit of $69.8 million. Net cash used in operating activities was $3.5 million for the quarter. Management estimates existing cash, together with proceeds from a July 2026 warrant exercise that raised approximately $2.6 million, will fund operations into but not beyond the first calendar quarter of 2027 and expects additional financing needs of about $25–$30 million to reach commercialization of its first indication. These conditions raise substantial doubt about its ability to continue as a going concern.
During the period, the company effected a 1-for-21 reverse stock split and subsequently regained compliance with Nasdaq’s $1.00 bid-price requirement. Capital structure is complex, with 512,394 potentially dilutive securities outstanding. Management reports ongoing material weaknesses in internal control over financial reporting, including lack of segregation of duties and technology control issues, and is adding personnel and consultants to improve controls.
Autonomix Medical, Inc. is conducting a primary at‑the‑market equity program, registering up to $1.35 million of common stock to be sold from time to time through Ladenburg Thalmann as sales agent or principal under an ATM Agreement.
The company had 971,043 shares outstanding as of July 29, 2026, with a potential increase to up to 1,266,447 shares based on an illustrative 295,404 shares sold at an assumed price of $4.57. Autonomix intends to use any net proceeds for working capital and general corporate purposes.
The filing highlights significant risks, including potential dilution, limited trading liquidity, dependence on additional financing, and exposure to Nasdaq’s new $5.0 million Market Value of Listed Securities requirement, which, if implemented and not met, could result in an immediate suspension and delisting of the stock. Audited financials also include a going‑concern explanatory paragraph.
Autonomix Medical, Inc. is registering up to 857,462 shares of common stock for resale by a single selling stockholder, issuable upon exercise of Series D warrants with a $5.75 exercise price. Autonomix is not selling any shares in this transaction and will receive cash only if the warrants are exercised for cash, which could total up to approximately $4.9 million in gross proceeds for working capital.
The warrants were issued in a July 2026 warrant inducement transaction tied to the exercise of Series C warrants that generated approximately $2.6 million in gross proceeds. As of July 27, 2026, 971,043 shares of common stock were outstanding, following a 1‑for‑21 reverse stock split that reduced shares outstanding from 11,409,344 to 542,349 while keeping 500 million authorized shares.
The company highlights that resale of a large block relative to shares outstanding could pressure the trading price and that full warrant exercise would materially dilute existing stockholders. Autonomix qualifies as an emerging growth company and its auditor has included a going concern explanatory paragraph in the latest annual financial statements.
Autonomix Medical, Inc. reported that as of July 28, 2026, its cash balance was approximately $5.1 million and it had 971,043 shares of common stock outstanding.
The outstanding share count includes common shares issued in connection with a warrant inducement dated July 13, 2026, providing an updated snapshot of the company’s cash position and capital structure.
Autonomix Medical, Inc. entered into a warrant inducement arrangement with an existing investor covering Series C/November 2025 warrants to purchase 428,731 shares of common stock. The company reduced the exercise price on these registered warrants to $6.00 per share, and the investor agreed to exercise them for anticipated gross proceeds of about $2.6 million, before fees and expenses.
In return, Autonomix will issue the investor two new unregistered warrant series, D-1 and D-2, each exercisable for up to 428,731 shares at $5.75 per share, with a 5.5-year term and beneficial ownership caps of 4.99% or 9.99%. The company committed to file, within 15 days, a resale registration statement for the shares underlying these new warrants and to seek effectiveness within 45 to 75 days, while paying Maxim Group LLC a 7.0% cash fee on warrant-exercise proceeds plus up to $15,000 of expenses.
Autonomix Medical, Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement for listing on the Nasdaq Capital Market. The company had previously received a Nasdaq deficiency notice on January 14, 2026 after its common stock closed below $1.00 per share for 30 consecutive business days. Nasdaq informed Autonomix on July 9, 2026 that the closing bid price was at or above $1.00 per share for 10 consecutive business days from June 24, 2026 through July 8, 2026, restoring compliance with Nasdaq Listing Rule 5550(a)(2). Nasdaq has indicated the matter is closed.